✦ LIBER ✦

Benzoxazinones as PPARγ Agonists. 2. SAR of the Amide Substituent and In Vivo Results in a Type 2 Diabetes Model

✍ Scribed by Rybczynski, Philip J.; Zeck, Roxanne E.; Dudash, Joseph; Combs, Donald W.; Burris, Thomas P.; Yang, Maria; Osborne, Melville C.; Chen, Xiaoli; Demarest, Keith T.

Book ID: 120200590
Publisher: American Chemical Society
Year: 2004
Tongue: English
Weight: 238 KB
Volume: 47
Category: Article
ISSN: 0022-2623
DOI: 10.1021/jm0301888

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PPARγ Agonist Pioglitazone Reverses Memo

PPARγ Agonist Pioglitazone Reverses Memory Impairment and Biochemical Changes in a Mouse Model of Type 2 Diabetes Mellitus

✍ Li-Ying Jiang; Su-Su Tang; Xiao-Yun Wang; Li-Ping Liu; Yan Long; Mei Hu; Ming-Xi 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 990 KB

Effects of peroxisome proliferator-activ

Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus

✍ M. Bajaj; S. Suraamornkul; L. J. Hardies; L. Glass; N. Musi; R. A. DeFronzo 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 195 KB

Ragaglitazar: The Pharmacokinetics, Phar

Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPARα and γ Agonist in Healthy Subjects and Patients with Type 2 Diabetes

✍ Skrumsager, B. K.; Nielsen, K. K.; Müller, M.; Pabst, G.; Drake, P. G.; Edsberg, 📂 Article 📅 2003 🏛 Sage Publications 🌐 English ⚖ 193 KB

The Pro12Ala polymorphism of PPARγ2 gene

The Pro12Ala polymorphism of PPARγ2 gene and susceptibility to type 2 diabetes mellitus in a Polish population

✍ Maciej T. Malecki; Jakub Frey; Tomasz Klupa; Jan Skupien; Malgorzata Walus; Wojc 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 202 KB

Toxicological consequences of altered pe

Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPARγ) expression in the liver: insights from models of obesity and type 2 diabetes

✍ Urs A. Boelsterli; Marc Bedoucha 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 124 KB

Efficacy and safety of the PPARγ partial

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

✍ Kim Henriksen; Inger Byrjalsen; Per Qvist; Henning Beck-Nielsen; Gitte Hansen; B 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB 👁 1 views

## Abstract ## Background Treatment of patients with perioxisome proliferator‐activated receptor‐γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator‐activated receptor‐γ agonists has not been esta